Protocol Ledger

NCT05820880 · Phase III · COMPLETED

Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension

Interventional Phase III clinical trial protocol NCT05820880 sponsored by Institut de Recherches Internationales Servier in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-06 Enrollment: 532 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05820880
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)532 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05820880
Protocol FieldVerified Registry Value
NCT IdentifierNCT05820880
Consolidated Lead SponsorInstitut de Recherches Internationales Servier
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment532 participants (ACTUAL)
Registered Start Date2019-05-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI